Myths11 min readUpdated 2026-03-14

    'You'll Gain It All Back': The Truth About GLP-1 Maintenance

    Addressing the myth that weight regain after GLP-1 is inevitable. Evidence-based maintenance strategies, what the data really shows, and how to build a lasting plan.

    Unpacking the Myth

    The claim "you'll just gain it all back" is perhaps the most common criticism of GLP-1 medications. It contains a kernel of truth—weight regain after stopping medication is common—but it is used to reach a false conclusion: that GLP-1 treatment is pointless.

    This is like saying blood pressure medication is pointless because your blood pressure will rise again if you stop taking it. Nobody says "you'll just get high blood pressure again" as an argument against treating hypertension. Obesity is a chronic disease that often requires ongoing management, and framing treatment as futile because it needs to continue is scientifically inaccurate and harmful.

    The STEP 1 extension study showed that participants who stopped semaglutide regained approximately two-thirds of lost weight within a year. But this data also shows that one-third of the weight loss was maintained even after stopping—and for participants who continued medication, weight loss was sustained. The conclusion should be "plan for maintenance," not "don't bother starting."

    What the Data Actually Shows

    100%
    Maintenance possible with continued medication
    ~33%
    Of weight loss maintained 1 year after stopping
    Variable
    Maintenance dose may preserve most results at lower cost

    Newer research on maintenance dosing strategies is promising. Studies examining lower-dose maintenance (semaglutide 1.0mg instead of 2.4mg after goal weight) show significant weight maintenance with fewer side effects and lower cost. The field is moving toward personalized maintenance protocols rather than the binary choice of "stay at full dose" or "stop completely."

    Five Evidence-Based Maintenance Strategies

    1. Transition to maintenance dosing

    Work with your provider to find the lowest effective maintenance dose. Many patients maintain successfully at 40-60% of their weight-loss dose.

    2. Prioritize resistance training

    Muscle is metabolically active. Building and maintaining muscle through strength training 3-4 times per week counteracts metabolic adaptation and helps maintain weight loss.

    3. Maintain high protein intake

    0.7-1.0 grams per pound of goal body weight daily. Protein preserves muscle, promotes satiety, and has a higher thermic effect (burns more calories during digestion).

    4. Set weight guardrails

    Establish a 5-7 pound "action zone" above your goal weight. If weight rises above this threshold, implement corrective measures immediately rather than waiting for significant regain.

    5. Continue monitoring

    Regular check-ins with your provider, ongoing self-weighing (weekly averages), and periodic body composition assessments help catch regain early when it is easiest to address.

    Even Temporary Weight Loss Has Lasting Benefits

    Even in the worst-case scenario—complete weight regain after stopping GLP-1—the period of lower weight produced health benefits that persist. Improved cardiovascular markers, reduced joint damage progression, improved liver health, and better glucose control during the treatment period all represent real health gains. And for many patients, the behavioral changes and improved relationship with food that developed during treatment persist even if some weight returns.

    Medical Disclaimer: This article is for educational purposes only. Never change your medication without consulting your healthcare provider.

    Frequently Asked Questions

    Is weight regain inevitable after stopping GLP-1?

    Significant weight regain is common (studies show ~66% regain within a year of stopping), but it is not inevitable. Patients who maintain strong exercise habits, adequate protein intake, and who work with their providers on gradual tapering or maintenance doses fare better than those who stop abruptly.

    Can I keep the weight off with lifestyle changes alone?

    Some patients can, but it requires rigorous and sustained effort against biological weight-regain mechanisms. The body fights to restore its previous weight through increased hunger and reduced metabolism. Most obesity medicine specialists recommend ongoing pharmacological support.

    What is a maintenance dose of GLP-1?

    A maintenance dose is a lower dose sufficient to maintain weight loss without further losing. For semaglutide, this might be 1.0-1.7mg instead of 2.4mg. For tirzepatide, 5-10mg instead of 15mg. Finding the minimum effective dose reduces side effects and cost while preserving results.

    Does this myth discourage people from trying GLP-1?

    Yes, significantly. Many people avoid starting treatment because they believe results are temporary. The reality is that even temporary weight loss produces lasting health benefits, and with proper planning, much of the weight loss can be maintained long-term.

    Plan for Lasting Results

    Our providers help you build a maintenance strategy from day one.

    Start Your Consultation

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 28, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.

    Complete guide covering affordable telehealth weight loss programs in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredients at up

    Complete guide covering the best online weight loss medication providers in 2026 in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ing

    Evidence-based guide on GLP-1 medications for African American women, addressing metabolic differences, health disparities, and culturally relevant strategies for weight management success.

    Start your GLP-1 journey — from $99/mo

    Get Started